Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting-Reference-Cited by-同舟云学术

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Published:2003 Issue:9 Volume:97 Page:2290-2300
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chawla Sant P.,Grunberg Steven M.,Gralla Richard J.,Hesketh Paul J.,Rittenberg Cindy,Elmer Mary E.,Schmidt Carrie,Taylor Arlene,Carides Alexandra D.,Evans Judith K.,Horgan Kevin J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

2. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

3. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993

4. Control of Chemotherapy-Induced Emesis

5. Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy;Biological and Pharmaceutical Bulletin;2024-06-19

2. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy;Expert Opinion on Pharmacotherapy;2023-11-27

3. Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis;Medicine;2023-11-24

4. The Role of Substance P and NK1 Receptors in Mild to Severe Traumatic Brain Injury: From CTE to ICP;Receptors;2023-11-11

5. Design and conduct considerations for studies in patients with hepatic impairment;Clinical and Translational Science;2022-10-09